STAR candidates for the treatment of Gaucher Disease enhance GCase activity in a neuronal cell model and reduce toxic accumulation of GCase substrate STAR candidates for the treatment of GM1 gangliosidosis and Morquio B increase β-gal maturation and delivery to the lysosome and enhance β-gal activity in a panel of fibroblast cell lines BETHESDA, Md., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and...
BETHESDA, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced that it will present three late-breaker abstracts at the 17th annual WORLDSymposium, a research conference dedicated to lysosomal diseases being held virtually February 8-12, 2021. The poster presentations will highlight data supporting Gain’s...
BETHESDA, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”) today announced the addition of Dov Goldstein, M.D., Gwen Melincoff, Claude Nicaise, M.D. and Hans Peter Hasler as independent members to its Board of Directors. The new board additions will provide strategic guidance as the company focuses on identifying and optimizing allosteric binding sites that have never before been targeted to unlock new treatment options for difficult-to-treat disorders characterized by...
Sep 28 ,2020
Pharmaceutical Technology
Treating lysosomal storage disorders: Gain and Sumitomo Dainippon enter partnership
|
Sep 10 ,2020
BioWorld
Gain Therapeutics Inc. signs a collaboration with Sumitomo Dainippon Pharma Co. Ltd.
|
Jul 24 ,2020
Endpoints
Jeff Capello out the door as Michael McDonnell takes over Biogens CFO post; Ron Bruehlman named interim CFO at IQVIA
|
January 6-8 & 11-14, 2021
Virtual
|
January 11-14, 2021
Virtual
|
December 16th 10:40am – 11:40 am est
Virtual
|